Page 10 - Pharma Sector

US pharma tariffs unlikely to hit Indian drugmakers materially: Ind-Ra

Ind-Ra said US tariffs may cause only short-term pricing impact for Indian pharma as firms remain fortified by diversification, strong balance sheets, and global market positioning

Turbocharging India: Assuming global economic leadership

Higher tariffs could render many Indian products uncompetitive in US markets and bring unfavourable repercussions to the domestic economy

Automobiles to pharma & healthcare: India Inc earnings stay in slow lane

Corporate profits remained weak in Q1FY26, amid single-digit growth in revenues for the ninth consecutive quarter

Shilpa Medicare share jumps 4% on 1:1 bonus issue; check record date here

Shilpa Medicare shares rose after the company announced a 1:1 bonus issue, with the Board approving the proposal in its meeting on August 13, 2025.

Mounjaro KwikPen by Lilly debuts in India at ₹14,000 for diabetes, obesity

Eli Lilly has launched its Mounjaro KwikPen in India at ₹14,000 for the 2.5 mg dose; the once-weekly injector targets diabetes and obesity, competing with Wegovy

Chemists urge crackdown on instant online delivery of high-risk medicines

Chemists' body urges action against e-pharmacies, quick commerce apps for delivering high-risk drugs without checks, warning of rising misuse and youth addiction

Pfizer share price up 3% on rolling out this vaccine; key details inside

Pfizer's share price gained today after the company announced the launch of its next-generation 20-valent pneumococcal conjugate vaccine (PCV20) for adults in India.

Pharma Inc mulls offshore strategy as US tariff fears hit sentiment

Despite current exemptions, Indian pharma firms are preparing for potential US tariffs through offshore units, EU market focus, and sourcing diversification

25% Donald Trump tariff likely to weigh on pharma margins: Analysts

The impact on innovator contract research, development and manufacturing organisations (CRDMOs) would be relatively lower

Ozempic maker's plight shows why managing markets matter for pharma giants

Novo's shares plunged amid rising competition, missed expectations, and governance issues, exposing the risks of neglecting market sentiment in high-growth pharma bets

India launches formal rules to fix, streamline drug and device clearances

India has issued first official guidelines for expert panels to bring consistency, speed, and transparency to drug and device approvals amid a broader regulatory overhaul

Indoco Remedies rises 6% on EU GMP certificate, trims gains after Q1 show

Indoco Remedies announced that it has received a Certificate of EU GMP Compliance from the European Health Authorities for its sterile drug product manufacturing facility at Goa Plant II.

Dr Reddy's Laboratories Q1 print misses target; brokerages split on outlook

Dr Reddy's Laboratories' posted a revenue of ₹8,545.2 crore, up 11 per cent year-on-year (Y-o-Y) but flat sequentially.

Results preview: Pharma firms stare at muted earnings growth for Q1

Indian pharma firms are set to post modest Q1FY26 earnings, with Revlimid erosion impacting US revenues and domestic growth moderating in chronic therapies

Glenmark, Laurus: 4 pharma stocks gain up to 79% in 5 months; time to exit?

The daily RSI, a key momentum indicator, shows that these 4 pharma stocks namely - Gland Pharma, Glenmark, Biocon and Laurus Labs are trading in the overbought territory; here's what to expect next.

Cipla buys 20% stake in iCaltech to broaden respiratory device portfolio

Cipla has acquired a 20% stake in iCaltech Innovations for Rs 5 crore, expanding its presence in the respiratory diagnostics segment with a strategic investment in medical device development

Sun Pharma's psoriasis drug delivers positive results in arthritis trials

Phase 3 trials show ILUMYA improved PsA symptoms significantly, with no new safety concerns; results support potential regulatory submissions in the US and globally

Here's what brokerages expect from Dr Reddy's Labs ahead of Q1 show

Dr Reddy's Labs Q1 preview: The company's net profit is expected to come at ₹1,460 crore, marking around 4.9 per cent Y-o-Y increase, on average, as against ₹1,392.4 crore in Q1 FY25

CDSCO revises export NOC guidance document for new drug formulations

The CDSCO has updated its guidelines for issuing export NOCs for new drug formulations, including relaxations for FDCs, research-oriented drug batches, and SRA approvals

CDSCO extends COPP application deadline for pharma units to August 15

Pharma firms get time till August 15 to file COPP applications online via ONDLS as CDSCO addresses onboarding challenges and industry pleas